Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
Read Article
The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient.
Read Article
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
Read Article
In the wake of the 2016 American Academy of Ophthalmology Guidelines, rheumatologists have dutifully reduced the dose of hydroxychloroquine (HCQ) take by patients with systemic lupus erythemato
Read Article
In research that surprised many at ACR Convergence 2022, a Dutch program targeting a whole food plant-based diet, physical activity, and stress management has shown benefit in DAS28 rheumatoid arthritis disease activity measures, just as ACR guidelines regarding exercise, diet and other integrati
Read Article
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.
Read Article
The last day was jammed with important reports and research including the late breaking abstracts.
Read Article
Interstitial Lung Disease (ILD) is common in rheumatoid arthritis (RA), occurring in approximately 8% of RA patients. It is associated with a poor prognosis, with a median survival of 3 years.
Read Article
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Read Article
On Thursday, November 21, 2022, Dr. Arthur Kavanaugh and Dr. Jack Cush reviewed the best and most interesting data and sessions presented at ACR22 in Philadelphia, PA. These are the research abstracts discussed:
Read Article
On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.
Read Article
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Read Article
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.
Read Article
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
Read ArticleInhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials (RCTs) have been inconsistent.
Read Article
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.
Read Article
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Read Article
Treat-to-target (T2T) management of systemic lupus erythematosus (SLE) has been shown to protect against organ damage and to improve quality of life.
Read Article
